164 related articles for article (PubMed ID: 38387940)
1. [Pathogenesis and Targeted Treatment Progress of Splenomegaly in Primary Myelofibrosis--Review].
Chen ZW; Wang SX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):308-312. PubMed ID: 38387940
[TBL] [Abstract][Full Text] [Related]
2. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
[TBL] [Abstract][Full Text] [Related]
3. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
4. P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
Spangrude GJ; Lewandowski D; Martelli F; Marra M; Zingariello M; Sancillo L; Rana RA; Migliaccio AR
Stem Cells; 2016 Jan; 34(1):67-82. PubMed ID: 26439305
[TBL] [Abstract][Full Text] [Related]
5. Modern management of splenomegaly in patients with myelofibrosis.
Tremblay D; Schwartz M; Bakst R; Patel R; Schiano T; Kremyanskaya M; Hoffman R; Mascarenhas J
Ann Hematol; 2020 Jul; 99(7):1441-1451. PubMed ID: 32417942
[TBL] [Abstract][Full Text] [Related]
6. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
7. Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly.
Kawano N; Saito N; Yoshida S; Kitanaka A; Shide K; Marutsuka K; Ohshima K; Shimoda K
Tohoku J Exp Med; 2022 Feb; 256(2):119-125. PubMed ID: 35173090
[TBL] [Abstract][Full Text] [Related]
8. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.
Migliaccio AR; Martelli F; Verrucci M; Migliaccio G; Vannucchi AM; Ni H; Xu M; Jiang Y; Nakamoto B; Papayannopoulou T; Hoffman R
Exp Hematol; 2008 Feb; 36(2):158-71. PubMed ID: 18206727
[TBL] [Abstract][Full Text] [Related]
9. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis: update on definition, pathogenesis, and treatment.
Abdel-Wahab OI; Levine RL
Annu Rev Med; 2009; 60():233-45. PubMed ID: 18947294
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Stem Cell Transplantation in Myelofibrosis.
Jain T; Mesa RA; Palmer JM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1429-1436. PubMed ID: 28499938
[TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
13. Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?
Sankar K; Pettit K
Curr Hematol Malig Rep; 2020 Oct; 15(5):391-400. PubMed ID: 32827272
[TBL] [Abstract][Full Text] [Related]
14. Evidence for organ-specific stem cell microenvironments.
Ghinassi B; Martelli F; Verrucci M; D'Amore E; Migliaccio G; Vannucchi AM; Hoffman R; Migliaccio AR
J Cell Physiol; 2010 May; 223(2):460-70. PubMed ID: 20112287
[TBL] [Abstract][Full Text] [Related]
15. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients.
Wang X; Cho SY; Hu CS; Chen D; Roboz J; Hoffman R
Exp Hematol; 2015 Feb; 43(2):100-9.e1. PubMed ID: 25461253
[TBL] [Abstract][Full Text] [Related]
16. Novel targets to cure primary myelofibrosis from studies on Gata1
Zingariello M; Martelli F; Verachi P; Bardelli C; Gobbo F; Mazzarini M; Migliaccio AR
IUBMB Life; 2020 Jan; 72(1):131-141. PubMed ID: 31749302
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.
Zingariello M; Martelli F; Ciaffoni F; Masiello F; Ghinassi B; D'Amore E; Massa M; Barosi G; Sancillo L; Li X; Goldberg JD; Rana RA; Migliaccio AR
Blood; 2013 Apr; 121(17):3345-63. PubMed ID: 23462118
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic myelofibrosis.
Barosi G; Hoffman R
Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]